Clinical Trial Update: Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive Impairment [Phase 2, Phase 3]

View source ↗

Summary

A study evaluating intrathecal idursulfase-IT with Elaprase in pediatric Hunter syndrome patients with early cognitive impairment has completed Phase 2/3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hunter Syndrome

Drugs mentioned

• Elaprase (idursulfase)
• Idursulfase-IT (idursulfase-IT)

Snippet

Sponsor: Shire | Conditions: Hunter Syndrome | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2018-12-13